Multiple orthobiologic companies have engaged in clinical trials in 2019, seeking to demonstrate the efficacy of their cell-based products….
GID BIO completed a multi-site, randomized, placebo-controlled Phase IIb clinical trial with an FDA-approved study design using autologous stromal cells in the treatment of knee osteoarthritis (OA), successfully meeting endpoints and two-year safety results…
Read more via BONEZONE.